









Markets
/
Stocks
/
nasdaq-nrsnw
/

Neurosense Therapeutics Ltd

NRSNW

View Detailed Chart

0.390USD

-0.310-43.06%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

0.00Market Cap

--P/E TTM



Neurosense Therapeutics Ltd

0.390

-0.310-43.06%

Overview Company Financials

Financials

Intraday

30m

Today

-43.06%

5 Days

-56.18%

1 Month

-43.45%

6 Months

+56.00%

Year to Date

-11.36%

1 Year

+129.41%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(7)

Neutral(3)

Buy(3)

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.016

Neutral

RSI(14)

47.840

Neutral

STOCH(KDJ)(9,3,3)

53.753

Sell

ATR(14)

0.391

Low Volatility

CCI(14)

-38.500

Neutral

Williams %R

61.000

Sell

TRIX(12,20)

1.338

Buy

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

0.674

Sell

MA10

0.582

Sell

MA20

0.550

Sell

MA50

0.497

Sell

MA100

0.349

Buy

MA200

0.283

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Ticker SymbolNRSNW

CompanyNeurosense Therapeutics Ltd

CEOMr. Alon Ben-Noon

Websitehttps://www.neurosense-tx.com/